Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.5B
93M shares
52-week range
$16.03 – $40.47
1% from low
Exchange
NASDAQ
ADRC
P/S (TTM)
1.5
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
www.ascentage.cnNo one on the platform currently holds AAPG.
No tracked institution reports a position in AAPG as of their last filing.
| Execution date | Ratio |
|---|---|
| 2003-04-07 | 3-for-1 |
No one on the platform has traded AAPG yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | -43.1% | 114.0% | ||||
| Profit Margin % | -216.5% | -779.8% | -2789.7% | |||
| Free Cash Flow Margin % | -215.2% | -947.5% | -2228.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $842M | +59.3% | $-7.75 | $-8.71–$-7.30 | — | 4 |
| 2027 | $1.9B | +126.1% | $-2.93 | $-909.38–$316.82 | — | 4 |
| 2028 | $2.6B | +38.9% | $-1.57 | $-3.14–$-0.71 | — | 2 |
| 2029 | $5.8B | +118.5% | $3.84 | $1.73–$7.67 | 4.2× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 4 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-20 | $0.02 | $-1.28 | -7840.4% |
| 2026-08-18 | $-0.22 | $-1.30 | -491.0% |
| 2026-03-24 | $-0.83 | $-0.65 | +21.7% |
| 2025-03-27 | $0.02 | $-1.00 | -6134.6% |
| $6.3B |
| — |
| IRONDisc Medicine, Inc. | $68.75 | -0.25% | $2.6B | — |
| LEGNLegend Biotech Corporation | $18.45 | -0.46% | $3.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
The big surprise? $AAPG is about to explode next week, closing the week on a 49.7% EPS estimate and heading into tomorrow’s open with a 71.7% boost. The 21.9pp jump means we’re looking at a strong catalyst for the weekend and beyond. https://app.k3vl4r.com/forecast/AAPG?utm_source=x&utm_medium=social&utm_campaign=signal&utm_content=AAPG #AAPG
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-8-19-ascentage-pharma-group-international-stock-1/ $AAPG Ascentage Pharma Group Internati
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.